Thank you for your interest in this scientific poster.

Assessment of the Oncomine™ cell-free DNA Lung Assay to Detect Low-Frequency Mutations using Reference Material

Plasma cell-free tumor DNA (cfDNA) from liquid biopsy is a potential source of tumor genetic material, which in the absence of tissue biopsy, can assist in early-stage diagnosis of lung cancer and monitoring treatment response. However, circulating levels of blood cfDNA vary significantly among patients and are generally low in early-stage disease requiring high-sensitivity assays.

In this study New York-Presbyterian Hospital evaluated the performance & capability of the Oncomine™ Lung cfDNA Assay to detect low-frequency somatic mutations at various amounts of input DNA, using standardized cfDNA reference material.

Related Content